Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,401–6,500 of 15,747
Speer, C., Morath, C. P., Töllner, M., Buylaert, M., Göth, D., Nußhag, C., Kälble, F., Schaier, M., Grenz, J., Kreysing, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.721286 · Cited by 15
Wojcechowskyj, J. A., Jong, R. M., Mäger, I., Flach, B., Munson, P. V., Mukherjee, P. P., Mertins, B., Barcay, K. R., & Folliard, T. (2025) · npj Vaccines · doi:10.1038/s41541-025-01135-8 · Cited by 15
Current challenges and perspectives in lung cancer care during COVID-19 waves
Mariniello, D. F., Aronne, L., Vitale, M., Schiattarella, A., Pagliaro, R., & Komici, K. (2023) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000967 · Cited by 15
“VACCINE IN PREVENTING SEVERE COVID19 AMONG LUNG CANCER PATIENTS In response to the global public health crisis caused by the COVID-19 pandemic, efforts were accelerated to develop safe and effective vaccines against SARSCoV-2 [33,34].”
BackgroundThe impact of COVID-19 on cancer patients
Wekking, D., Senevirathne, T. H., Pearce, J. L., Aiello, M. M., Scartozzi, M., Lambertini, M., Silva, P. D., & Solinas, C. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.004 · Cited by 15
Guidelines for Infection Control and Burnout Prevention in Healthcare Workers Responding to COVID-19
Park, S. Y., Cheong, H. S., Kwon, K. T., Sohn, K. M., Heo, S. T., Lee, S., Chung, U., & Lee, S. H. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2022.0164 · Cited by 15
A comprehensive review on efficient approaches for combating coronaviruses
Pouresmaieli, M., Ekrami, E., Akbari, A., Noorbakhsh, N., Moghadam, N. B., & Mamoudifard, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112353 · Cited by 13
Zhou, Z., Du, P. F., Li, N., Xiong, X., Tang, S., Dai, Q., Wang, T., Yu, M., Man, M., Lam, K., et al. (2022) · MedComm · doi:10.1002/mco2.143 · Cited by 13
MRI Negative Myelitis Induced by Pfizer-BioNTech COVID-19 Vaccine
Cabral, G., Gonçalves, C., Serrazina, F., et al. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.1.120 · Cited by 12
Structural characterization of mRNA lipid nanoparticles (LNPs) in the presence of mRNA-free LNPs
Chen, X., Ye, Y., Li, M., Zuo, T., Xie, Z., Ke, Y., Cheng, H., Hong, L., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114082 · Cited by 23
Spatial-temporal differences of COVID-19 vaccinations in the U.S.
Huang, Q., & Cutter, S. L. (2022) · Urban Informatics · doi:10.1007/s44212-022-00019-9 · Cited by 11
“Safety and efficacy results for vaccines were over 90% against symptomatic and severe diseases caused by contagion of COVID-19 (Anderson et al., 2020; Polack et al., 2020; Voysey et al., 2021).”
BackgroundMcCaughan, G. J. B., Ciaccio, P. R. D., Ananda-Rajah, M. R., Gilroy, N. M., MacIntyre, C. R., Teh, B. W., Weinkove, R., Curnow, J. L., Szer, J., Enjeti, A. K., et al. (2021) · Internal Medicine Journal · doi:10.1111/imj.15247 · Cited by 14
Fornaro, M., Venerito, V., Iannone, F., et al. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.210863 · Cited by 12
Goldman, J. D., Gonzalez, M. A., Rüthrich, M. M., Sharon, E., & von Lilienfeld‐Toal, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_359656 · Cited by 14
Ou, W., Wang, B., Zhang, G., Ding, L., Liu, Z., Wu, K., Sun, G., Huang, C., Li, Z., Feng, S., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1123385 · Cited by 15
“To date, four variants of the disease have been documented: (1) type I: coronary spasm in patients with (nearly) normal coronary arteries; (2) type II: coronary thrombosis in patients with underlying asymptomatic CHD; (3) type III: stent-related allergic Frontiers in Cardiovascular Medicine 04 coronary events, with II…”
BackgroundMethodInfluentialSpeich, B., Chammartin, F., Smith, D. C., Stoeckle, M. P., Amico, P., Eichenberger, A. L., Hasse, B. K., Schuurmans, M. M., Müller, T., Tamm, M., et al. (2021) · Trials · doi:10.1186/s13063-021-05664-0 · Cited by 13
Choi, J. H., Kang, K. S., & Han, K. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2059308 · Cited by 12
“Among the solicited systemic adverse events of BNT162b2 vaccination, headache, and fatigue are common, while gastrointestinal symptoms, such as vomiting (1–3%) and diarrhea (4–11%), are uncommon, regardless of age.(3,4) A similar distribution of adverse events occurred in Korean adolescents.”
BackgroundLin, T.-C., Fu, P., Hsu, Y., & Chen, T. (2023) · Vaccines · doi:10.3390/vaccines11061115 · Cited by 14
Dugani, S. B., Fischer, K. M., Schroeder, D. R., Geyer, H. L., Maniaci, M. J., Croghan, I. T., Kashani, D., & Burton, M. C. (2022) · Journal of Hospital Medicine · doi:10.1002/jhm.12812 · Cited by 11
de Bock, E., Herman, E. S., Bastian, O. W., Filipe, M. D., Vriens, M. R., & Richir, M. C. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101859 · Cited by 15
Seguridad de las vacunas contra la COVID-19
Chaparro-Mérida, N. A., Samper, D. M., & Lacato, A. O. F. (2021) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2021.384.9308 · Cited by 25
Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery
Żak, M. M., Kaur, K., Yoo, J., Kurian, A. A., Adjmi, M., Mainkar, G., Yoon, S., & Zangi, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092176 · Cited by 13
“Recommended dosages of modRNA vaccines for adults are 30 µg of modRNA for the Pfizer/BioNTech’s and 100 µg for the Moderna’s [40,41].”
MethodQi, X., Wang, J., Zhang, Q., Ai, J., Liu, C., Li, Q., Gu, Y., Lv, J., Huang, Y., Liu, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27992 · Cited by 12
COVID-19 vaccines surveillance in France: a global response to a major national challenge
Benkebil, M., Gautier, S., Gras‐Champel, V., et al. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100866 · Cited by 12
Facing up to the COVID-19 pandemic in Argentina
Rabinovich, G. A., & Geffner, J. R. (2021) · Nature Immunology · doi:10.1038/s41590-021-00873-w · Cited by 12
The lymphatic system and COVID-19 vaccines
Miyasaka, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041025 · Cited by 12
“A two-dose series of either of these mRNA vaccines has been shown to markedly reduce the risk of not only symptomatic infection but also hospitalization and mortality from COVID-19 (7, 8).”
BackgroundCheng, F.-S., Yen, Y., Lin, S.-Y., Weng, S., Chou, Y.-C., Chu, D., Chen, C.-C., & Hu, H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18158065 · Cited by 13
“Two recent reports showed that the PfizerBioNTech or Moderna two-dose COVID-19 vaccine regimen had a 94–95% efficacy at preventing symptomatic SARS-CoV-2 infection [10,11].”
ResultAlshamrani, M. M., Farahat, F. M., El‐Saed, A., Alzunitan, M. A., Alsaedi, A., Gammal, A. E., Nasser, W. A., Nazeer, S. H., & Almohrij, S. A. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.11.015 · Cited by 12
“Consistent with current findings, data pubished at the time of the study (early 2021) showed that 91%–96% of ost-vaccination infections occurred before full protection, at least ne week after the second dose [7,9].”
Vollenberg, R., Tepasse, P., Lorentzen, E. U., & Nowacki, T. M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050694 · Cited by 12
The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
Liu, Y., & Ye, Q. (2023) · Vaccines · doi:10.3390/vaccines11091472 · Cited by 12
Wang, S., Noumi, B., Malik, F., & Wang, S. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01357-0 · Cited by 11
“The most common reported side effects are injection site reactions and systemic events including fatigue, headache, myalgias, arthralgia, fever, and chills [3].”
El‐Shitany, N. A., Bagher, A. M., Binmahfouz, L. S., Eid, B. G., Almukadi, H. S., Badr-Eldin, S. M., El‐Hamamsy, M., Mohammedsaleh, Z. M., Saleh, F. M., Almuhayawi, M. S., et al. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s376316 · Cited by 13
“The maximum effect is about 95%, reached one week after the 2 dose.(4,5) Despite the high infection rate of the SARS-CoV-2 virus, the double dose of Pfizer BioNTech’s COVID-19 vaccination program effectively reduced hospitalization and mortality rates.”
BackgroundPalandri, F., Breccia, M., Stefano, V. D., & Passamonti, F. (2021) · Cancers · doi:10.3390/cancers13194750 · Cited by 13
Massonnaud, C., Roux, J., Colizza, V., & Crépey, P. (2022) · Vaccines · doi:10.3390/vaccines10030479 · Cited by 18
Anti‐TNF therapy impairs both short‐ and long‐term IgG responses after repeated vaccination
Buhre, J. S., Pongrácz, T., Geisen, U. M., Schubert, M., Wang, W., Nouta, J., Obara, M., Lehrian, S., Rahmöller, J., Petry, J., et al. (2024) · Allergy · doi:10.1111/all.16241 · Cited by 16
SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy
Marcianò, G., Roberti, R., Palleria, C., Mirra, D., Rania, V., Casarella, A., Sarro, G. D., & Gallelli, L. (2021) · Applied Sciences · doi:10.3390/app11167457 · Cited by 12
El-Araby, R. E., Tu, Q., Xie, Y., Aboushousha, T., Li, Z., Xu, X., Zhu, Z. X., Dong, L., & Chen, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.0162 · Cited by 15
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
Yap, T. A., Siu, L. L., Calvo, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00017-6 · Cited by 12
An overview of some potential immunotherapeutic options against COVID-19
Bayat, M., Asemani, Y., Mohammadi, M. R., Sanaei, M., Namvarpour, M., & Eftekhari, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107516 · Cited by 12
Al‐Muhaiteeb, A., AlSahow, A., Alyousef, A., Alhelal, B. A., AlRajab, H., Bahbahani, Y., dewidar, N., & Fanous, G. N. M. (2022) · Hemodialysis International · doi:10.1111/hdi.13005 · Cited by 13
“Food Drug Agency approved the emergency use of the Pfizer BNT162B2 vaccine for the prevention of COVID-19 in individuals aged 16 and older.(1) This approval was based on a clinical trial that included healthy volunteers.”
MethodThe clinical potential of l -oligonucleotides: challenges and opportunities
Shearer, V., Yu, C., Han, X., & Sczepanski, J. T. (2024) · Chemical Science · doi:10.1039/d4sc05157b · Cited by 17
COVID-19 and Management Scholarship: Lessons for Conducting Impactful Research
George, G., Ertug, G., Bapuji Hari, B., Doh, J. P., Mair, J., & Prasad, A. (2024) · Business & Society · doi:10.1177/00076503241237047 · Cited by 11
“The next two most-cited articles reported the effectiveness of a treat-ment (Horby et al., 2020) and the efficacy of a mRNA vaccine (Polack et al., 2020).”
Background(2021) · doi:10.1101/2021.10.30.21265693 · Cited by 12
“Introduction Severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine is a powerful tool to control the coronavirus disease-2019 (COVID-19) pandemic and the mRNA vaccine BNT162b2 (Pfizer-BioNTech, USA) is reported to have an vaccine efficacy of 95% [1].”
BackgroundJapan’s Special Approval for Emergency System During the COVID‐19 Pandemic
Maeda, H. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2310 · Cited by 17
Imai, K., Tanaka, F., Kawano, S., Esaki, K., Arakawa, J., Nishiyama, T., Seno, S., Hatanaka, K., Sugiura, T., Kodama, Y., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.07.027 · Cited by 12
Homma, K., Miura, Y., Kobayashi, M., Chintrakulchai, W., Toyoda, M., Ogi, K., Michinishi, J., Ohtake, T., Honda, Y., Nomoto, T., et al. (2024) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2024.2338785 · Cited by 14
“Comirnaty [5] have recently been demonstrated as effective therapeutics.”
BackgroundCould Guillain–Barré syndrome be triggered by COVID‐19 vaccination?
Aldeeb, M. A., Okar, L., Mahmud, S. S., et al. (2022) · Clinical Case Reports · doi:10.1002/ccr3.5237 · Cited by 12
Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19Preprint
Kapłonek, P., Wang, C., Bartsch, Y. C., Fischinger, S., Gorman, M. J., Bowman, K. A., Kang, J., Dayal, D., Martin, P., Nowak, R. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.11.443609 · Cited by 12
Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events
Noh, Y., Ko, H. Y., Kim, J. H., Yoon, D., Choe, Y. J., Choe, S., Jung, J., & Shin, J. (2023) · Epidemiology and Health · doi:10.4178/epih.e2023054 · Cited by 15
COVID-19 in Women's health: Epidemiology
Jardine, J. E., & Morris, E. (2021) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.03.010 · Cited by 15
Sugiyama, A., Kurisu, A., Nagashima, S., Hando, K., Saipova, K., Akhmedova, S., Abe, K., Imada, H., Hussain, M. R. A., Ouoba, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20747-x · Cited by 13
Comprehensive Understanding and Field Application of COVID-19 Vaccine
Choi, W. S. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.3.155 · Cited by 11
Yuan, X., Yao, Y., Li, X., & Feng, M. (2024) · Nonlinear Dynamics · doi:10.1007/s11071-024-09832-0 · Cited by 13
Matsuura, T., Fukushima, W., Nakagama, Y., Kido, Y., Kase, T., Kondo, K., Kaku, N., Matsumoto, K., Suita, A., Mukai, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57931-0 · Cited by 14
Rajlic, I. L., Guglieri-López, B., Rangoonwala, N., Ivaturi, V. D., Van, L. M., Mori, S., Wipke, B. T., Burdette, D. S., & Attarwala, H. Z. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13142 · Cited by 13
“24,25 mRNA-based COVID-19 vaccines developed by Moderna and Pfizer/BioNTech demonstrated remarkable efficacy and safety in phase III trials, 26,27 as well as in real-world adoption.”
BackgroundImpact of waning immunity against SARS-CoV-2 severity exacerbated by vaccine hesitancy
Saad-Roy, C. M., Morris, S. E., Boots, M., Baker, R. E., Lewis, B. L., Farrar, J., MARATHE, M. V., Graham, A. L., Levin, S. A., Wagner, C. E., et al. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012211 · Cited by 20
Muscle Regeneration and RNA: New Perspectives for Ancient Molecules
Buonaiuto, G., Desideri, F., Taliani, V., & Ballarino, M. (2021) · Cells · doi:10.3390/cells10102512 · Cited by 12
“By December 2020, two mRNA-based vaccines (Moderna and Pfizer/BioNTech) completed the clinical trials, started to be administrated at a large scale [7], and gave successful performances in producing high and persisting titers of antibodies [8].”
BackgroundCancer Patients and the COVID-19 Vaccines: Considerations and Challenges
Almasri, M., Bshesh, K., Khan, W., Mushannen, M., Salameh, M., Shafiq, A., Vattoth, A. L., Elkassas, N., & Zakaria, D. (2022) · Cancers · doi:10.3390/cancers14225630 · Cited by 11
Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
Phan, J. M., Layton, E. D., Yu, K. K. Q., Aguilar, M. S., Golez, I., Franko, N., Logue, J. K., Rodda, L. B., Howard, C. A., Pepper, M., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200815 · Cited by 13
Lamptey, E., Senkyire, E. K., Serwaa, D., Aki, B. D., Boakye, E. O., Ikome, T., & Asamoah, A. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.2.193 · Cited by 12
“The lessons from this strategy over time were applied for the development for use as COVID-19 vaccines [33].”
BackgroundMethod(2021) · doi:10.1101/2021.05.03.21256509 · Cited by 12
“In particular, the rate of local symptoms is substantially lower than the ones observed in other approved anti-COVID vaccine trials for what concern age groups similar to our sample (>60 years) [13,14].”
BackgroundResultLee, H., Punt, J. A., Miller, D. C., Nagpal, A., Smith, C., Sayeed, Y. A., Patel, J., Stojanovic, M. P., Popescu, A., & McCormick, Z. L. (2021) · Pain Medicine · doi:10.1093/pm/pnab063 · Cited by 12
Eusébio, D., Paul, M., Biswas, S., Cui, Z., Costa, D. R. B., & Sousa, Â. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123959 · Cited by 13
MAM: Flexible Monte-Carlo Agent based model for modelling COVID-19 spread
De-Leon, H., & Aran, D. (2023) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2023.104364 · Cited by 13
“Here, VE was set to 0% on days 0-7 after the first dose of vaccination and increases linearly up to 90% on the next 21 days, which is also one week after the second dose ( Figure S2A ) [26, 27].”
BackgroundTrends in COVID-19 Vaccine Hesitancy and Uptake Among Persons Living With HIV in Washington, DC
Castel, A. D., Barth, S. K., Wilbourn, B. C., Horberg, M. A., Monroe, A. K., & Greenberg, A. E. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003243 · Cited by 12
Kumar, R., Beniwal, K., Bahurupi, Y. A., Kant, R., & Bairwa, M. C. (2021) · Korean Journal of Family Medicine · doi:10.4082/kjfm.21.0071 · Cited by 13
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
Psichοgiou, M., Karabinis, A., Poulakou, G., Antoniadou, A., Kotanidou, Α., Degiannis, D., Pavlopoulou, I. D., Chaidaroglou, A. S., Roussos, S., Mastrogianni, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9091017 · Cited by 13
“6%) in preventing symptomatic COVID-19 disease ≥7 days after the 2nd dose [2].”
BackgroundImplementation of mRNA–Lipid Nanoparticle Technology in Atlantic Salmon (Salmo salar)
Dahl, L. O. S., Hak, S., Braaen, S., Molska, A., Rodà, F., Parot, J., Wessel, Ø., Fosse, J. H., Bjørgen, H., Borgos, S. E., et al. (2024) · Vaccines · doi:10.3390/vaccines12070788 · Cited by 17
“The success of mRNA vaccines against COVID-19 has demonstrated their potential in preventing infectious diseases [9,10].”
BackgroundLi, R., Hu, J., Li, R., He, Y., Wang, X., Lin, X., Li, W., Wu, Y., Kuwentrai, C., Su, C., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00743-3 · Cited by 18
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study
Puthanakit, T., Prompetchara, E., Gatechompol, S., Ketloy, C., Thitithanyanont, A., Jongkaewwattana, A., Buranapraditkun, S., Ubolyam, S., Kerr, S. J., Sophonphan, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-49653-6 · Cited by 11
“These phase 2 results have further confirmed the findings of our phase 1 study, that ChulaCov19 elicited robust and strong specific immunogenicity like those of the approved mRNA vaccines, despite its differences 6,12 .”
BackgroundResultInfluentialAbid, A., Khan, M. A., Lee, B. W. H., White, A. J. R., Carnt, N. A., Arshad, S., & Samarawickrama, C. (2022) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1155/2022/9970922 · Cited by 13
Clinical Development of mRNA Vaccines: Challenges and Opportunities
August, A., Brito, L., Paris, R., & Zaks, T. Z. (2022) · Current topics in microbiology and immunology · doi:10.1007/82_2022_259 · Cited by 14
Modeling SARS‐CoV‐2 True Infections in Catalonia through a Digital Twin
Casas, P. F. I., Subirana, J. G. I., & Carrasco, V. G. I. (2023) · Advanced Theory and Simulations · doi:10.1002/adts.202200917 · Cited by 13
Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
Aliaga, P. T., Trapani, D., Sandoval, J. L., Crimini, E., Antonarelli, G., Vivanet, G., Morganti, S., Corti, C., Tarantino, P., Friedlaender, A., et al. (2021) · Cancers · doi:10.3390/cancers13225829 · Cited by 11
“, Pfizer-BioNTech (Cambridge, MA, USA) [2] and Moderna (Cambridge, MA, USA) [3–5]), and two are viral vector-based (i.”
Representation of Race and Sex in Sleep Surgery Studies
Debbaneh, P. M., Ramirez, K. A., Block, N., & Durr, M. L. (2022) · Otolaryngology · doi:10.1177/01945998221088759 · Cited by 13
Breakthrough SARS-CoV-2 infections after vaccination: a critical review
Afshar, Z. M., Barary, M., Hosseinzadeh, R., Alijanpour, A., Hosseinzadeh, D., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2051412 · Cited by 14
“Some studies have shown that the mRNA vaccines, Moderna and Pfizer, have an efficacy of up to 95% for preventing symptomatic SARS-CoV-2 infection 7–14 days after the second dose.(10,11) However, it should be noted that mild antibody decreases, following natural- or vaccine-induced immunity does not necessarily indicat…”
ResultBatot, C., Chea, M., Zeidan, S., Mongin, M., Pop, G., Mazoyer, J., & Degos, B. (2022) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.688 · Cited by 12
Casmil, I. C., Friesen, J. J., Bathula, N. V., Strumpel, A., Ho, C.-H., Guez, I., Kong, K. Y. S., Varley, A., Miyake-Stoner, S. J., Aliahmad, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202508907 · Cited by 20
Zhang, Y., Chen, C., Su, M., Wang, J., Li, C., & Yang, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c04507 · Cited by 12
Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain
(2021) · doi:10.1101/2021.01.26.428356 · Cited by 77
Monti, S. M., Fornara, C., Delvino, P., Bartoletti, A., Bergami, F., Comolli, G., Sammartino, J. C., Biglia, A., Cassione, E. B., Cassaniti, I., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac365 · Cited by 14
“as 95% against infection and even higher in preventing severe disease in the first trials(3,4).”
BackgroundMorello, R., Pepe, M., Martino, L., Lazzareschi, I., Chiaretti, A., Gatto, A., & Curatola, A. (2022) · Acta Paediatrica · doi:10.1111/apa.16462 · Cited by 11
Neurological manifestations associated with COVID-19 vaccine
Castillo, R. A., & Martínez‐Castrillo, J. C. (2022) · Neurología (English Edition) · doi:10.1016/j.nrleng.2022.09.007 · Cited by 19
Virk, A., Johnson, M. G., Roellinger, D. L., Scott, C. G., Sampathkumar, P., Breeher, L. E., & Swift, M. D. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad161 · Cited by 10
Alwafi, H. H., Naser, A. Y., Aldhahir, A. M., Alhazmi, A., Alosaimi, A. N., Mandili, R. A., Majeed, Z., Salawati, E. M., Ekram, R., Samannodi, M. S., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07905-2 · Cited by 16
“A relatively small number of patients experienced a severe systemic reaction [14–16].”
BackgroundImpact of COVID-19 Vaccination on Menstrual Cycle: A Cross-Sectional Study From Karachi, Pakistan
Sualeh, M., Uddin, M. R., Junaid, N., Khan, M., Pario, A., & Ain, Q. (2022) · Cureus · doi:10.7759/cureus.28630 · Cited by 27
“Several factors can influence menstrual patterns; coagulopathy, ovulatory dysfunction, medication use, and modifiable factors (sudden weight loss, over-exercising, obesity, psychological disorders) all are considered [9].”
BackgroundProgress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Li, Y., Lu, S.-M., Wang, J.-L., Yao, H., & Liang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33179 · Cited by 15
“The latest on the use of vaccines. primary efficacy endpoint requirements, with protective efficacy of 94.1 % and 95.0 %, respectively, and consistent efficacy in different age, gender, and ethnic groups [61].”
BackgroundInfluentialThe immunopathogenesis of SARS-CoV-2 infection: Overview of lessons learned in the first 5 years
Yang, O. O. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf033 · Cited by 16
Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults
Shapiro, J. R., Morgan, R., Leng, S. X., & Klein, S. L. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.836642 · Cited by 13
“The COVID-19 vaccine clinical trials revealed remarkably high efficacy against the ancestral virus at all ages but did not provide estimates disaggregated by sex within each age group (Baden et al., 2020; Polack et al., 2020; Falsey et al., 2021; Sadoff et al., 2021).”
BackgroundZhang, Y., Zhuang, X., Hu, Y., Chen, J., Hao, K., Tang, Z., Tian, M., Tian, H., Jin, N., & Chen, X. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00365 · Cited by 12
Oh, S., Purja, S., Shin, H., Kim, M. S., Park, S., Kronbichler, A., Smith, L., Eisenhut, M., Shin, J. I., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10101572 · Cited by 12
“Confirmed COVID-19 was defined according to the FDA criteria as symptoms of cough and fever [3].”
MethodVogrig, M., Berger, A.-E., Bourlet, T., Waeckel, L., Haccourt, A., Chanavat, A. H., Hupin, D., Roche, F., Botelho-Nevers, É., Pozzetto, B., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01354-x · Cited by 14
MacFadden, D. R., Maxwell, C. J., Bowdish, D. M. E., Bronskill, S. E., Brooks, J., Brown, K. A., Burrows, L. L., Clarke, A. M., Langford, B. J., Leung, E., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad190 · Cited by 12
“It is generally accepted that COVID-19 vaccination reduces the incidence and severity of COVID-19 infection [16, 17].”
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 12
Prabhu, M., Yang, Y. J., Johnston, C. D., Murphy, E. A., Ketas, T. J., Diaz-Tapia, R., Jurkiewicz, M., Racine‐Brzostek, S., Mohammed, I. A., Sukhu, A. C., et al. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100796 · Cited by 16
“These findings are substantiated by the noted clinical efficacy of SARS-CoV-2 vaccination in pregnancy in other cohorts that is comparable to the efficacy in nonpregnant individuals.(3,16) In addition, the peak and longitudinal anti-S IgG response among pregnant participants at 6 to 8 months post peak is similar to th…”
ResultReview: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 13
Basson, Y. P.-P., Tayer-Shifman, O. E., Naser, R., Matalon, S. T., Kimhi, O., Gepstein, R., Halperin, T., Ziv‐Baran, T., Ziv, A., Parikh, R., et al. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06348-z · Cited by 15
“1 3 (BNT162b2) vaccine encodes a genetically modified SARS-CoV-2 spike S protein [1] that is reported to elicit high titers of neutralizing antibodies to the virus in the vast majority of the vaccinated individuals [2].”
BackgroundGavriilaki, E., Παπαδοπούλου, Α., Touloumenidou, T., Stavridou, F., Koravou, E., Giannaki, M., Papalexandri, A., Karavalakis, G., Batsis, I., Kourelis, A., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01675-w · Cited by 13
“Notwithstanding the prioritization of HCT recipients to COVID19 vaccination, limited information is available on whether and to what extent, they could mount functional immune responses as they were generally excluded from vaccination trials [4].”
BackgroundProfiles of US Hispanics Unvaccinated for COVID-19
Piper, B. J., Sanchez, B. V., Madera, J. D., et al. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01245-2 · Cited by 12
“” The continued emergence of new variants makes the earlier randomized controlled trials [21, 22] less helpful for efficacy information, but these well-powered datasets are still valuable to inform short-term safety.”
BackgroundOka, E., Ueda, Y., Yagi, A., Ito, Y., Hosokawa, Y., Tabuchi, T., & Kimura, T. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100441 · Cited by 13
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.